These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 18096759)
21. The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Peng XQ; Ashby CR; Spiller K; Li X; Li J; Thomasson N; Millan MJ; Mocaër E; Muńoz C; Gardner EL; Xi ZX Neuropharmacology; 2009 Mar; 56(4):752-60. PubMed ID: 19136017 [TBL] [Abstract][Full Text] [Related]
22. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. Loiseau F; Millan MJ Eur Neuropsychopharmacol; 2009 Jan; 19(1):23-33. PubMed ID: 18793829 [TBL] [Abstract][Full Text] [Related]
23. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. Millan MJ; Di Cara B; Dekeyne A; Panayi F; De Groote L; Sicard D; Cistarelli L; Billiras R; Gobert A J Neurochem; 2007 Feb; 100(4):1047-61. PubMed ID: 17266737 [TBL] [Abstract][Full Text] [Related]
24. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930 [TBL] [Abstract][Full Text] [Related]
25. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. Millan MJ; Schreiber R; Dekeyne A; Rivet JM; Bervoets K; Mavridis M; Sebban C; Maurel-Remy S; Newman-Tancredi A; Spedding M; Muller O; Lavielle G; Brocco M J Pharmacol Exp Ther; 1998 Sep; 286(3):1356-73. PubMed ID: 9732399 [TBL] [Abstract][Full Text] [Related]
26. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337 [TBL] [Abstract][Full Text] [Related]
27. Neuropsychopharmacological profile of remoxipride in comparison with clozapine. Skuza G; Rogóz Z; Wieczorek A Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546 [TBL] [Abstract][Full Text] [Related]
28. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Gyertyán I; Kiss B; Sághy K; Laszy J; Szabó G; Szabados T; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Csongor EÁ; Domány G; Tihanyi K; Szombathelyi Z Neurochem Int; 2011 Nov; 59(6):925-35. PubMed ID: 21767587 [TBL] [Abstract][Full Text] [Related]
29. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Brocco M; Dekeyne A; Papp M; Millan MJ Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388 [TBL] [Abstract][Full Text] [Related]
30. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors. Witkin JM; Levant B; Zapata A; Kaminski R; Gasior M J Pharmacol Exp Ther; 2008 Sep; 326(3):930-8. PubMed ID: 18566292 [TBL] [Abstract][Full Text] [Related]
31. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418 [TBL] [Abstract][Full Text] [Related]
32. Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor. Yarkov AV; Der TC; Joyce JN Eur J Pharmacol; 2010 Feb; 627(1-3):167-72. PubMed ID: 19900441 [TBL] [Abstract][Full Text] [Related]
34. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Zhang M; Ballard ME; Unger LV; Haupt A; Gross G; Decker MW; Drescher KU; Rueter LE Behav Brain Res; 2007 Aug; 182(1):1-11. PubMed ID: 17570538 [TBL] [Abstract][Full Text] [Related]
35. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. Gobert A; Di Cara B; Cistarelli L; Millan MJ J Pharmacol Exp Ther; 2003 Apr; 305(1):338-46. PubMed ID: 12649387 [TBL] [Abstract][Full Text] [Related]